It looks like the BOD is now focused on commercializing ganetespib and are gearing up to get the approval and then land a subsequent partnership to market the product around the World for various cancer treatments. This is all starting to make sense...it seems that Bernitz was probably released because it became apparent that it was way too premature to work on a meaningful, successful partnership at this particular point in time. The new goal of getting FDA approval and then seeking a mutual positive partnership to take the drug to market sounds like a great plan that will reap rewards for all of us shareholders. The hiring of Anne Whitaker is the perfect icing on the cake that will facilitate the successful implementation of the new plan. I am liking what I am seeing and hope that I can accumulate more before the price goes much higher.